BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update
Tóm tắt
Từ khóa
Tài liệu tham khảo
Llovet, 1999, Prognosis of hepatocellular carcinoma: the BCLC staging classification, Semin Liver Dis, 19, 329, 10.1055/s-2007-1007122
Forner, 2010, Current strategy for staging and treatment: the BCLC update and future prospects, Semin Liver Dis, 30, 61, 10.1055/s-0030-1247133
Reig, 2014, Systemic therapy for hepatocellular carcinoma: the issue of treatment stage migration and registration of progression using the BCLC-refined RECIST, Semin Liver Dis, 34, 444
Bruix, 2016, Evidence-based diagnosis, staging, and treatment of patients with hepatocellular carcinoma, Gastroenterology, 150, 835, 10.1053/j.gastro.2015.12.041
Hernán, 2021, Methods of public health research - strengthening causal inference from observational data, N Engl J Med, 385, 10.1056/NEJMp2113319
Schag, 1984, Karnofsky performance status revisited: reliability, validity, and guidelines, J Clin Oncol, 2, 187, 10.1200/JCO.1984.2.3.187
Sorensen, 1993, Performance status assessment in cancer patients. An inter-observer variability study, Br J Cancer, 67, 773, 10.1038/bjc.1993.140
Pugh, 1973, Transection of the oesophagus for bleeding oesophageal varices, Br J Surg, 60, 646, 10.1002/bjs.1800600817
Kamath, 2001, A model to predict survival in patients with end-stage liver disease, Hepatology, 33, 464, 10.1053/jhep.2001.22172
Kim, 2008, Hyponatremia and mortality among patients on the liver-transplant waiting list, N Engl J Med, 359, 1018, 10.1056/NEJMoa0801209
Kim, 2021, MELD 3.0: the model for end-stage liver disease updated for the modern era, Gastroenterology, 10.1053/j.gastro.2021.08.050
Johnson, 2015, Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade, J Clin Oncol, 33, 550, 10.1200/JCO.2014.57.9151
Pinato, 2017, The ALBI grade provides objective hepatic reserve estimation across each BCLC stage of hepatocellular carcinoma, J Hepatol, 66, 338, 10.1016/j.jhep.2016.09.008
Scheiner, 2021, Predicting the outcome of patients with hepatocellular carcinoma treated with immunotherapy-the CRAFITY score, J Hepatol, 75, S236
Singal, 2021, International liver cancer association (ILCA) white paper on biomarker development for hepatocellular carcinoma, Gastroenterology, 160, 2572, 10.1053/j.gastro.2021.01.233
Cabibbo, 2012, Natural history of untreatable hepatocellular carcinoma: a retrospective cohort study, World J Hepatol, 4, 256, 10.4254/wjh.v4.i9.256
de Franchis, 2015, Expanding consensus in portal hypertension, J Hepatol, 63, 743, 10.1016/j.jhep.2015.05.022
D’Amico, 2018, Clinical states of cirrhosis and competing risks, J Hepatol, 68, 563, 10.1016/j.jhep.2017.10.020
Garcia-Tsao, 2010, Now there are many (stages) where before there was one: in search of a pathophysiological classification of cirrhosis, Hepatology, 51, 1445, 10.1002/hep.23478
Tonon, 2021, Outcomes and mortality of grade 1 ascites and recurrent ascites in patients with cirrhosis, Clin Gastroenterol Hepatol, 19, 358, 10.1016/j.cgh.2020.03.065
Llach, 1988, Prognostic value of arterial pressure, endogenous vasoactive systems, and renal function in cirrhotic patients admitted to the hospital for the treatment of ascites, Gastroenterology, 94, 482, 10.1016/0016-5085(88)90441-6
Pinyol, 2019, Molecular predictors of prevention of recurrence in HCC with sorafenib as adjuvant treatment and prognostic factors in the phase 3 STORM trial, Gut, 68, 1065, 10.1136/gutjnl-2018-316408
Vogel, 2018, Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†, Ann Oncol, 29, iv238, 10.1093/annonc/mdy308
Galle, 2018, EASL clinical practice guidelines: management of hepatocellular carcinoma, J Hepatol, 69, 182, 10.1016/j.jhep.2018.03.019
Heimbach, 2018, AASLD guidelines for the treatment of hepatocellular carcinoma, Hepatology, 67, 358, 10.1002/hep.29086
Bruix, 2021, Systemic treatment of hepatocellular carcinoma. An EASL position paper, J Hepatol, 75, 960, 10.1016/j.jhep.2021.07.004
Gordan, 2020, Systemic therapy for advanced hepatocellular carcinoma: ASCO guideline, J Clin Oncol, 38, 4317, 10.1200/JCO.20.02672
Pocock, 2016, The primary outcome is positive — is that good enough?, N Engl J Med, 375, 971, 10.1056/NEJMra1601511
Forner, 2014, Treatment of intermediate-stage hepatocellular carcinoma, Nat Rev Clin Oncol, 11, 525, 10.1038/nrclinonc.2014.122
Bruix, 2011, Clinical decision making and research in hepatocellular carcinoma: pivotal role of imaging techniques, Hepatology, 54, 2238, 10.1002/hep.24670
Templeton, 2020, Informative censoring — a neglected cause of bias in oncology trials, Nat Rev Clin Oncol, 17, 327, 10.1038/s41571-020-0368-0
Sala, 2004, High pathological risk of recurrence after surgical resection for hepatocellular carcinoma: an indication for salvage liver transplantation, Liver Transpl, 10, 1294, 10.1002/lt.20202
Fuks, 2012, Benefit of initial resection of hepatocellular carcinoma followed by transplantation in case of recurrence: an intention-to-treat analysis, Hepatology, 55, 132, 10.1002/hep.24680
Ferrer-Fàbrega, 2016, Prospective validation of ab initio liver transplantation in hepatocellular carcinoma upon detection of risk factors for recurrence after resection, Hepatology, 63, 839, 10.1002/hep.28339
Cho, 2010, Hepatic resection versus radiofrequency ablation for very early stage hepatocellular carcinoma: a Markov model analysis, Hepatology, 51, 1284, 10.1002/hep.23466
Cucchetti, 2013, Cost-effectiveness of hepatic resection versus percutaneous radiofrequency ablation for early hepatocellular carcinoma, J Hepatol, 59, 300, 10.1016/j.jhep.2013.04.009
Izumi, 2019, A multicenter randomized controlled trial to evaluate the efficacy of surgery vs. radiofrequency ablation for small hepatocellular carcinoma (SURF trial), J Clin Oncol, 37, 10.1200/JCO.2019.37.15_suppl.4002
Doyle, 2019, Outcomes of radiofrequency ablation as first-line therapy for hepatocellular carcinoma less than 3 cm in potentially transplantable patients, J Hepatol, 70, 866, 10.1016/j.jhep.2018.12.027
Mazzaferro, 1996, Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis, N Engl J Med, 334, 693, 10.1056/NEJM199603143341104
Yao, 2001, Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival, Hepatology, 33, 1394, 10.1053/jhep.2001.24563
Mazzaferro, 2009, Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis, Lancet Oncol, 10, 35, 10.1016/S1470-2045(08)70284-5
Duvoux, 2012, Liver transplantation for hepatocellular carcinoma: a model including alpha-fetoprotein improves the performance of Milan criteria, Gastroenterology, 143, 985, 10.1053/j.gastro.2012.05.052
Mazzaferro, 2018, Metroticket 2.0 model for analysis of competing risks of death following liver transplantation for hepatocellular carcinoma, Gastroenterology, 154, 128, 10.1053/j.gastro.2017.09.025
Herrero, 2008, Liver transplantation in patients with hepatocellular carcinoma across Milan criteria, Liver Transpl, 14, 272, 10.1002/lt.21368
Citterio, 2016, Hierarchic interaction of factors associated with liver decompensation after resection for hepatocellular carcinoma, JAMA Surg, 151, 846, 10.1001/jamasurg.2016.1121
Llovet, 1999, Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation, Hepatology, 30, 1434, 10.1002/hep.510300629
Berzigotti, 2015, Portal hypertension and the outcome of surgery for hepatocellular carcinoma in compensated cirrhosis: a systematic review and meta-analysis, Hepatology, 61, 526, 10.1002/hep.27431
Bruix, 1996, Surgical resection of hepatocellular carcinoma in cirrhotic patients: prognostic value of preoperative portal pressure, Gastroenterology, 111, 1018, 10.1016/S0016-5085(96)70070-7
Ferrusquía-Acosta, 2021, Agreement between wedged hepatic venous pressure and portal pressure in non-alcoholic steatohepatitis-related cirrhosis, J Hepatol, 74, 811, 10.1016/j.jhep.2020.10.003
Baffy, 2021, Overlooked subclinical portal hypertension in non-cirrhotic NAFLD: is it real and how to measure it?, J Hepatol
Chen, 2006, A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma, Ann Surg, 243, 321, 10.1097/01.sla.0000201480.65519.b8
Ng, 2017, Randomized clinical trial of hepatic resection versus radiofrequency ablation for early-stage hepatocellular carcinoma, Br J Surg, 104, 1775, 10.1002/bjs.10677
Feng, 2012, A randomized controlled trial of radiofrequency ablation and surgical resection in the treatment of small hepatocellular carcinoma, J Hepatol, 57, 794, 10.1016/j.jhep.2012.05.007
Nault, 2018, Percutaneous treatment of hepatocellular carcinoma: state of the art and innovations, J Hepatol, 68, 783, 10.1016/j.jhep.2017.10.004
Berardi, 2020, Development of a nomogram to predict outcome after liver resection for hepatocellular carcinoma in Child-Pugh B cirrhosis, J Hepatol, 75, 10.1016/j.jhep.2019.08.032
Sposito, 2016, Propensity score analysis of outcomes following laparoscopic or open liver resection for hepatocellular carcinoma, Br J Surg, 103, 871, 10.1002/bjs.10137
Molina, 2018, Benefits of laparoscopic liver resection in patients with hepatocellular carcinoma and portal hypertension: a case-matched study, Surg Endosc, 32, 2345, 10.1007/s00464-017-5930-1
Witowski, 2019, Meta-analysis of short- and long-term outcomes after pure laparoscopic versus open liver surgery in hepatocellular carcinoma patients, Surg Endosc, 33, 1491, 10.1007/s00464-018-6431-6
Morise, 2015, Can we expand the indications for laparoscopic liver resection? A systematic review and meta-analysis of laparoscopic liver resection for patients with hepatocellular carcinoma and chronic liver disease, J Hepatobil Pancreat Sci, 22, 342, 10.1002/jhbp.215
Ciria, 2016, Comparative short-term benefits of laparoscopic liver resection: 9000 cases and climbing, Ann Surg, 263, 761, 10.1097/SLA.0000000000001413
Pompili, 2013, Long-term effectiveness of resection and radiofrequency ablation for single hepatocellular carcinoma ≤3 cm. Results of a multicenter Italian survey, J Hepatol, 59, 89, 10.1016/j.jhep.2013.03.009
N’Kontchou, 2009, Radiofrequency ablation of hepatocellular carcinoma: long-term results and prognostic factors in 235 Western patients with cirrhosis, Hepatology, 50, 1475, 10.1002/hep.23181
Shiina, 2012, Radiofrequency ablation for hepatocellular carcinoma: 10-year outcome and prognostic factors, Am J Gastroenterol, 107, 569, 10.1038/ajg.2011.425
Cucchetti, 2015, When to perform hepatic resection for intermediate-stage hepatocellular carcinoma, Hepatology, 61, 905, 10.1002/hep.27321
Forner, 2014, Heterogeneity of intermediate-stage HCC necessitates personalized management including surgery, Nat Rev Clin Oncol, 12
Takayasu, 2006, Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients, Gastroenterology, 131, 461, 10.1053/j.gastro.2006.05.021
Galle, 2017, The treatment of intermediate stage tumours beyond TACE: from surgery to systemic therapy, J Hepatol, 67, 173, 10.1016/j.jhep.2017.03.007
Kloeckner, 2021, Local and regional therapies for hepatocellular carcinoma, Hepatology, 73, 137, 10.1002/hep.31424
Mehta, 2020, Liver transplantation for hepatocellular carcinoma. Working group report from the ILTS transplant oncology consensus conference, Transplantation, 1136, 10.1097/TP.0000000000003174
Kwong, 2021, Expanding the limits of liver transplantation for hepatocellular carcinoma: is there a limit?, Clin Liver Dis, 25, 19, 10.1016/j.cld.2020.08.002
Ferrer-Fàbrega, 2021, Limited tumour progression beyond Milan criteria while on the waiting list does not result in unacceptable impairment of survival, J Hepatol, 10.1016/j.jhep.2021.06.015
Navasa, 2010, Multifaceted perspective of the waiting list for liver transplantation: the value of pharmacokinetic models, Hepatology, 51, 12, 10.1002/hep.23332
Toso, 2015, Total tumor volume and alpha-fetoprotein for selection of transplant candidates with hepatocellular carcinoma: a prospective validation, Hepatology, 62, 158, 10.1002/hep.27787
Mehta, 2019, Alpha-fetoprotein decrease from >1000 to <500 ng/ml in patients with hepatocellular carcinoma leads to improved post-transplant outcomes, Hepatology, 69, 1193, 10.1002/hep.30413
Finn, 2020, Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma, N Engl J Med, 382, 1894, 10.1056/NEJMoa1915745
Cheng, 2009, Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial, Lancet Oncol, 10, 25, 10.1016/S1470-2045(08)70285-7
Llovet, 2008, Sorafenib in advanced hepatocellular carcinoma, N Engl J Med, 359, 378, 10.1056/NEJMoa0708857
Kudo, 2018, Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial, Lancet, 391, 1163, 10.1016/S0140-6736(18)30207-1
Abou-Alfa, 2022, Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA, J Clin Oncol, 40, 379, 10.1200/JCO.2022.40.4_suppl.379
Kelley, 2021, VP10-2021: cabozantinib (C) plus atezolizumab (A) versus sorafenib (S) as first-line systemic treatment for advanced hepatocellular carcinoma (aHCC): results from the randomized phase III COSMIC-312 trial, Ann Oncol
Bruix, 2017, Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial, Lancet, 389, 56, 10.1016/S0140-6736(16)32453-9
Abou-Alfa, 2018, Cabozantinib in patients with advanced and progressing hepatocellular carcinoma, N Engl J Med, 379, 54, 10.1056/NEJMoa1717002
Finn, 2018, Outcomes of sequential treatment with sorafenib followed by regorafenib for HCC: additional analyses from the phase III RESORCE trial, J Hepatol, 69, 353, 10.1016/j.jhep.2018.04.010
Zhu, 2019, Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial, Lancet Oncol, 20, 282, 10.1016/S1470-2045(18)30937-9
Finn, 2020, Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: a randomized, double-blind, phase III trial, J Clin Oncol, 38, 193, 10.1200/JCO.19.01307
Qin S, Chen Z, Fang W, Ren Z, Xu R, l Ryoo BY et al. Pembrolizumab plus best supportive care versus placebo plus best supportive care as second-line therapy in patients in Asia with advanced hepatocellular carcinoma (HCC): Phase 3 KEYNOTE-394 study. J Clin Oncol 2022 40:4_suppl, 383–383. https://ascopubs.org/doi/10.1200/JCO.2022.40.4_suppl.383
Shiina, 2005, A randomized controlled trial of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma, Gastroenterology, 129, 122, 10.1053/j.gastro.2005.04.009
Germani, 2010, Clinical outcomes of radiofrequency ablation, percutaneous alcohol and acetic acid injection for hepatocelullar carcinoma: a meta-analysis, J Hepatol, 52, 380, 10.1016/j.jhep.2009.12.004
Burrel, 2012, Survival of patients with hepatocellular carcinoma treated by transarterial chemoembolisation (TACE) using Drug Eluting Beads. Implications for clinical practice and trial design, J Hepatol, 56, 1330, 10.1016/j.jhep.2012.01.008
Salem, 2021, Yttrium-90 radioembolization for the treatment of solitary, unresectable hepatocellular carcinoma: the LEGACY study, Hepatology, 74, 2342, 10.1002/hep.31819
Chen, 2020, Role of external beam radiotherapy in hepatocellular carcinoma, Clin Liver Dis, 24, 701, 10.1016/j.cld.2020.07.006
Shanker, 2021, Stereotactic ablative radiotherapy for hepatocellular carcinoma: a systematic review and meta-analysis of local control, survival and toxicity outcomes, J Med Imaging Radiat Oncol, 10.1111/1754-9485.13309
Yu, 2017, Percutaneous cooled-probe microwave versus radiofrequency ablation in early-stage hepatocellular carcinoma: a phase III randomised controlled trial, Gut, 66, 1172, 10.1136/gutjnl-2016-312629
Vietti Violi, 2018, Efficacy of microwave ablation versus radiofrequency ablation for the treatment of hepatocellular carcinoma in patients with chronic liver disease: a randomised controlled phase 2 trial, Lancet Gastroenterol Hepatol, 3, 317, 10.1016/S2468-1253(18)30029-3
Han, 2020, Radiofrequency ablation versus microwave ablation for early stage hepatocellular carcinoma: a PRISMA-compliant systematic review and meta-analysis, Medicine (Baltimore), 99, 10.1097/MD.0000000000022703
Chan, 2018, Development of pre and post-operative models to predict early recurrence of hepatocellular carcinoma after surgical resection, J Hepatol, 69, 1284, 10.1016/j.jhep.2018.08.027
Vitale, 2015, Survival benefit of liver resection for patients with hepatocellular carcinoma across different Barcelona Clinic Liver Cancer stages: a multicentre study, J Hepatol, 62, 617, 10.1016/j.jhep.2014.10.037
Vouche, 2013, Radiation lobectomy: time-dependent analysis of future liver remnant volume in unresectable liver cancer as a bridge to resection, J Hepatol, 59, 1029, 10.1016/j.jhep.2013.06.015
Troisi, 2021, Laparoscopic and open liver resection for hepatocellular carcinoma with Child–Pugh B cirrhosis: multicentre propensity score-matched study, Br J Surg, 108, 196, 10.1093/bjs/znaa041
Reverter, 2019, The prognostic role of hepatic venous pressure gradient in cirrhotic patients undergoing elective extrahepatic surgery, J Hepatol, 71, 942, 10.1016/j.jhep.2019.07.007
Fukami, 2020, Liver resection for multiple hepatocellular carcinomas: a Japanese nationwide survey, Ann Surg, 272, 145, 10.1097/SLA.0000000000003192
Raoul, 2019, Updated use of TACE for hepatocellular carcinoma treatment: how and when to use it based on clinical evidence, Cancer Treat Rev, 72, 28, 10.1016/j.ctrv.2018.11.002
Golfieri, 2014, Randomised controlled trial of doxorubicin-eluting beads vs conventional chemoembolisation for hepatocellular carcinoma, Br J Cancer, 111, 255, 10.1038/bjc.2014.199
Varela, 2007, Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics, J Hepatol, 46, 474, 10.1016/j.jhep.2006.10.020
Lammer, 2010, Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study, Cardiovasc Interv Radiol, 33, 41, 10.1007/s00270-009-9711-7
Meyer, 2013, A randomised phase II/III trial of 3-weekly cisplatin-based sequential transarterial chemoembolisation vs embolisation alone for hepatocellular carcinoma, Br J Cancer, 108, 1252, 10.1038/bjc.2013.85
Brown, 2016, Randomized trial of hepatic artery embolization for hepatocellular carcinoma using doxorubicin-eluting microspheres compared with embolization with microspheres alone, J Clin Oncol, 34, 2046, 10.1200/JCO.2015.64.0821
Facciorusso, 2017, Transarterial chemoembolization vs bland embolization in hepatocellular carcinoma: a meta-analysis of randomized trials, United Eur Gastroenterol J, 5, 511, 10.1177/2050640616673516
Hameed, 2014, Alpha-fetoprotein level > 1000 ng/mL as an exclusion criterion for liver transplantation in patients with hepatocellular carcinoma meeting the Milan criteria, Liver Transpl, 20, 945, 10.1002/lt.23904
Mazzaferro, 2020, Liver transplantation in hepatocellular carcinoma after tumour downstaging: a randomised, controlled, phase 2/3 trial, Lancet Oncol, 21, 947, 10.1016/S1470-2045(20)30224-2
Yao, 2015, Downstaging of hepatocellular cancer before liver transplant: long-term outcome compared to tumors within Milan criteria, Hepatology, 61, 1968, 10.1002/hep.27752
Bruix, 2021, End-points in clinical trials for liver cancer and their value in evidence based clinical decision making: an unresolved Gordian knot, J Hepatol, 74, 1483, 10.1016/j.jhep.2021.01.033
Ho, 2021, Neoadjuvant cabozantinib and nivolumab convert locally advanced hepatocellular carcinoma into resectable disease with enhanced antitumor immunity, Nat Cancer, 2, 891, 10.1038/s43018-021-00234-4
Sangro, 2011, Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: a European evaluation, Hepatology, 54, 868, 10.1002/hep.24451
Mazzaferro, 2013, Yttrium-90 radioembolization for intermediate-advanced hepatocellular carcinoma: a phase 2 study, Hepatology, 57, 1826, 10.1002/hep.26014
Hilgard, 2010, Radioembolization with yttrium-90 glass microspheres in hepatocellular carcinoma: European experience on safety and long-term survival, Hepatology, 52, 1741, 10.1002/hep.23944
Chow, 2018, SIRveNIB: selective internal radiation therapy versus sorafenib in Asia-Pacific patients with hepatocellular carcinoma, J Clin Oncol, 36, 1913, 10.1200/JCO.2017.76.0892
Vilgrain, 2017, Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial, Lancet Oncol, 18, 1624, 10.1016/S1470-2045(17)30683-6
Ricke, 2019, Impact of combined selective internal radiation therapy and sorafenib on survival in advanced hepatocellular carcinoma, J Hepatol, 71, 1164, 10.1016/j.jhep.2019.08.006
Reig, 2013, Post-progression survival of patients with advanced hepatocellular carcinoma. Rationale for second line trial design, Hepatology, 58, 2023, 10.1002/hep.26586
Iavarone, 2015, Predictors of survival of patients with advanced hepatocellular carcinoma who permanently discontinued sorafenib, Hepatology, 62, 784, 10.1002/hep.27729
Reig, 2021, Pattern of progression in advanced hepatocellular carcinoma treated with ramucirumab, Liver Int, 41, 598, 10.1111/liv.14731
Rimassa, 2018, Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study, Lancet Oncol, 19, 682, 10.1016/S1470-2045(18)30146-3